(276) An open-label, Multicenter Study of the Safety, Pharmacokinetics, and Effectiveness of Buprenorphine Transdermal System (BTDS) in Children from 7 to 16 years of age, Inclusive, who Required Continuous Opioid Analgesia for Moderate to Severe Pain